中国临床药理学杂志2018，Vol.34Issue(19)：2287-2290,4.DOI:10.13699/j.cnki.1001-6821.2018.19.013
重组人干扰素α1b注射液联合阿糖腺苷注射剂治疗手足口病的临床研究
Clinical trial of recombinant human interferon α1b injection combined with vidarabine injection in the treatment of hand foot and mouth disease
摘要
Abstract
Objective To observe the clinical efficacy and safety of re-combinant human interferon α1b injection combined with vidarabine injec-tion in the treatment of hand foot and mouth disease (HFMD).Methods A total of 94 children with HFMD were randomly divided into control and treatment groups with 47 cases per group.Control group received re-combinant human interferon α1b injection 6-20 μg· d-1, qd, intramus-cular injection.Treatment group was given vidarabine injection 5 -10 mg· kg-1· d-1, qd, intravenous drip, on the basis of control group . Two groups were treated for 5 days.The clinical efficacy , levels of serum immunoglobulin M (IgM), IgG, IgA, creatine kinase(CK), creatine ki-nase isoenzyme ( CK-MB), lactate dehydrogenase ( LDH) and lactate dehydrogenase isoenzyme (LDH-1), and adverse drug reactions were compared between two groups .Results After treatment, the total effective rates of treatment and control groups were 97.87%(46 cases/47 cases)and 72.34%(34 cases/47 cases) with significant difference (P <0.05).After treatment, the main indexes in treatment and control groups were compared : IgM were ( 1.44 ±0.19 ) and ( 1.27 ±0.16 ) g· L-1, IgG were ( 9.08 ±1.28 ) and (8.47 ±1.17 ) g· L-1, IgA were ( 1.09 ±0.14 ) and ( 0.91 ±0.10 ) g· L-1, CK were ( 72.27 ±10.06 ) and (97.25 ±12.63 ) U· L-1, CK -MB were ( 19.94 ±2.66 ) and ( 32.14 ±4.17 ) U· L-1, LDH were (207.48 ±28.13) and (313.26 ±42.27)U· L-1, LDH-1 were (53.39 ±7.17) and (78.27 ±10.81)U· L-1, the differences were statistically significant ( P<0.05 or P<0.01 ) .The adverse drug reactions of treatment group were leukopenia, skin pruritus and rash during the infusion of adenosine monophosphate , while those in the control group were leucopenia.The total incidences of adverse drug reactions in treatment and control groups were 4.25%and 2.13%without significant difference ( P >0.05 ) . Conclusion Recombinant human interferon α1b injection combined with vidarabine injection has a definitive clinical efficacy in the treatment of HFMD , without increasing the incidence of adverse drug reactions .关键词
重组人干扰素α1b注射液/阿糖腺苷注射剂/手足口病/安全性Key words
recombinant human interferon α1b injection/vidarabine injection/hand foot and mouth disease/safety分类
医药卫生引用本文复制引用
蔡丽云,姚敏,王永卿,魏小斌,郑青,符先先,冯焕玉,张素领..重组人干扰素α1b注射液联合阿糖腺苷注射剂治疗手足口病的临床研究[J].中国临床药理学杂志,2018,34(19):2287-2290,4.基金项目
海南省卫生计生行业科研基金资助项目(15A200054) （15A200054）
